Home » Stocks » TRIL

Trillium Therapeutics Inc. (TRIL)

Stock Price: $11.72 USD 0.37 (3.26%)
Updated Mar 1, 2021 11:32 AM EST - Market open
Market Cap 1.16B
Revenue (ttm) 94,656
Net Income (ttm) -31.77M
Shares Out 14.69M
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $11.72
Previous Close $11.35
Change ($) 0.37
Change (%) 3.26%
Day's Open 11.52
Day's Range 11.52 - 11.87
Day's Volume 561,371
52-Week Range 2.50 - 20.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.

Other stocks mentioned: AMZN, BMY, GILD, INFI, NVAX, RHHBY, SHOP, WMT
The Motley Fool - 1 month ago

The cancer biotech soared in 2020, jumping up over 1,000% for the year. What will the stock do in 2021?

Seeking Alpha - 1 month ago

Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor spac...

The Motley Fool - 1 month ago

Buy these three biotech stocks before they take off.

Other stocks mentioned: AMGN, ILMN
The Motley Fool - 1 month ago

When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.

The Motley Fool - 1 month ago

Biotech, bitcoin, and renewable energy led the way.

Other stocks mentioned: BEEM, BLNK, BTBT, CRDF, MARA, NIO, NVAX, RIOT, VXRT
The Motley Fool - 1 month ago

The company's long-term plan is to challenge conventional cancer therapy.

The Motley Fool - 1 month ago

This clinical-stage biotech stock could be a top buyout candidate in 2021.

The Motley Fool - 1 month ago

Find out what these healthcare businesses can do to deliver big gains this year.

Other stocks mentioned: NNOX, TDOC
Benzinga - 2 months ago

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited f...

Other stocks mentioned: CRDF, GNPX, NVAX, VXRT
Zacks Investment Research - 2 months ago

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

The Motley Fool - 2 months ago

A decline in the stock price plus positive clinical data equals opportunity.

The Motley Fool - 2 months ago

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CLDX, CODX, CRDF, MCRB, MRNA, NSRGY, NVAX, VXRT
Zacks Investment Research - 2 months ago

Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Motley Fool - 2 months ago

The micro-cap has shot up an incredible 1,400% this year.

The Motley Fool - 2 months ago

A new CEO and prioritization of research could have more big gains in store for the company

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innov...

The Motley Fool - 2 months ago

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, MRSN, SURF
The Motley Fool - 3 months ago

Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative th...

Seeking Alpha - 3 months ago

Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity i...

GlobeNewsWire - 3 months ago

Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board

The Motley Fool - 3 months ago

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

Other stocks mentioned: ADAP
GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innov...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative ...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...

Zacks Investment Research - 5 months ago

Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Motley Fool - 5 months ago

Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher.

Other stocks mentioned: SRNE
GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...

Benzinga - 5 months ago

Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and T...

Other stocks mentioned: PFE
The Motley Fool - 5 months ago

Trillium lands a noteworthy equity stake from pharma titan Pfizer.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovati...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovativ...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative...

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapie...

Investopedia - 8 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, VNDA, VRTX, XBIT
Benzinga - 9 months ago

Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Friday, after the company provided an update on TTI-622 at ASCO.

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

The Motley Fool - 10 months ago

Keep your eyes on these two stocks in the months to come.

Other stocks mentioned: BDSI
Zacks Investment Research - 10 months ago

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

Seeking Alpha - 10 months ago

Trillium Therapeutics: Runup Expected For This CD47 Player Ahead Of Midyear Update

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovati...

About TRIL

Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecul... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Dr. Jan Skvarka
Stock Exchange
NASDAQ
Ticker Symbol
TRIL
Full Company Profile

Financial Performance

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for TRIL stock is "Strong Buy." The 12-month stock price forecast is 11.02, which is a decrease of -5.97% from the latest price.

Price Target
$11.02
(-5.97% downside)
Analyst Consensus: Strong Buy